Kyorin Pharmaceutical Co., Ltd.

Teijin Pharma Limited

Other

Masanori Takadoi

Yasumichi Fukuda

Yoshikazu Asahina

Masanori Yamamoto

Yasuo Takano

Takashi Hirayama

Atsuhiro Yamanishi

Shinji Kobayashi

Shiro Terashima

Naoki Ando

Kohei Ohata

Tomohiro Ide

Tsuyoshi Anraku

Kei Okazaki

Futoshi Shiga

Masaya Takei

Kazunori Fukuchi

Jun Asano

Fumiyoshi Kobayashi

Hideyuki Fukuda

Kanji Komatsu

Akihiro Ishiwata

Hiroyuki Ebisu

Taro Sato

Tadashi Katoh

Hideharu Uchiki

Junichiro Uda

Haruaki Kurasaki

A compound having a hypoglycemic effect is provided. The compound and a pharmaceutically acceptable salt thereof are useful for the treatment or prevention of diabetes, obesity, and the like. The compound is represented by the general formula (1): (wherein Rand Rare each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a Cto Calkyl group, a Cto Calkoxy group, a Cto Calkylsulfanyl group, a Cto Calkylsulfinyl group, a Cto Calkylsulfonyl group, or a Cto Calkoxy-Cto Calkylsulfonyl group, and A is a substituted or unsubstituted heteroaryl group).

Cyclopentylacrylamide derivative

To provide a novel mutilin derivative having a substitution at the 14-position, which is a novel mutilin analogue exhibiting a potent and broad antimicrobial action against Gram-positive bacteria and Gram-negative bacteria including various drug-resistant bacteria, and which is expected to be useful as an agent for treating infectious diseases. A mutilin derivative represented by the following general formula (1): or a pharmaceutically acceptable addition salt thereof.

Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position

A compound, or a pharmaceutically acceptable salt thereof, represented by the formula (1), (wherein, the carbon atom marked with an * is in the R-configuration, Rrepresents a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C-Calkyl group, or a C-Calkoxy group, Rrepresents a C-Ccycloalkylsulfanyl group, a C-Ccycloalkylsulfinyl group, or a C-Ccycloalkylsulfonyl group, and A represents a substituted or unsubstituted heteroaryl group).

Glucokinase activator

Hydronaphtho&lsqb;2,3-c&rsqb;furan derivatives and process for the preparation thereof

6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, addition salts thereof, and processes for the preparation of both

Imidazolidinone derivatives, their acid adducts and therapeutic drugs

Anti-dementia medicaments comprising a carbamic acid derivative or their pharmaceutically acceptable acid addition salts having an anti-amnesic activity as an active ingredient are provided. The carbamic acid derivatives are represented by a general formula (1) ##STR1## wherein Ar denotes an aromatic heterocyclic ring which may have at least one substituent or its benzene-condensed ring, or phenyl group which may have at least one substituent, R.sup.1 denotes hydrogen atom or lower alkyl group, R.sup.2 denotes lower alkyl group which may be substituted with halogen atom, phenyl group which may have at least one substituent, naphthyl group, or five- or six-membered heterocyclic ring and its benzene-condensed ring, X and Y, which may be the same or different, denote sulfur atom or oxygen atom.

Carbamic acid derivatives and method for preparing the same

Growing community of inventors

Tochigi, Japan

Masanori Takadoi